



The 16th Annual Congress on Controversies in Ophthalmology: COPHy 2025
April 4-5, Seville, Spain

COPHy 2025 – PRELIMINARY PROGRAM as of February 10, 2025

FRIDAY, APRIL 4, 2025		
08:30-10:00	BIG CONTROVERSIES IN RETINA AND BEYOND IN 2025	HALL A
Chairs:	<u>Baruch Kuppermann</u> , USA; <u>Anat Loewenstein</u> , Israel	
08:30-08:40	Welcome Remarks <u>Baruch Kuppermann</u> , USA; <u>Anat Loewenstein</u> , Israel	
08:40-09:00	Keynote Lecture:	
08:40-08:55	Retinal Implants to Restore Vision <u>Mark Humayun</u> , USA	
08:55-09:00	Q&A	
09:00-09:30	Debate 1: Will topical therapy become the standard of care for either prevention or delay of myopia progression?	
09:00-09:10	Yes: TBC	
09:10-09:20	No: <u>Hakan Kaymak</u> , Germany	
09:20-09:30	Discussion	
09:30-10:00	Debate 2: Gene Therapy for NVAMD will be the preferred therapy in the future	
09:30-09:40	Yes: <u>Luis Arias</u> , Spain	
09:40-09:50	No: <u>Paolo Lanzetta</u> , Italy	
09:50-10:00	Discussion	
10:00-10:30	Coffee Break, Visit Exhibition, View ePosters & join us in the Speaker's Corner	EXHIBITION AREA



FRIDAY, APRIL 4, 2025			
HALL A		HALL B	
10:30-12:00	MEDICAL RETINA 1 Neovascular (“Wet”) AMD Management	10:30-12:00	GLAUCOMA 1
Chairs:	<u>Luis Arias</u> , Spain; <u>Francesco Bandello</u> , Italy; <u>Rufino Silva</u> , Portugal	Chairs:	<u>Francesca Cordeiro</u> , UK
10:30-11:00	Debate 1: New generation anti-VEGF agents are specifically beneficial for pigment epithelial detachment	10:30-11:00	Debate 1: Phaco alone is better than Phaco Plus MIGS
10:30-10:40	Yes: <u>Francesco Bandello</u> , Italy	10:30-10:40	Yes: <u>Joel Suarez</u> , Spain
10:40-10:50	No: <u>Patricia Udaondo</u> , Spain	10:40-10:50	No: <u>Marta Pazos</u> , Spain
10:50-11:00	Discussion	10:50-11:00	Discussion
11:00-11:30	Debate 2: Home monitoring has the potential to improve patient outcome in AMD	11:00-11:30	Debate 2: Clinicians decisions are better than AI decisions in Glaucoma
11:00-11:10	Yes: <u>Anat Loewenstein</u> , Israel	11:00-11:10	Yes: <u>Francesca Cordeiro</u> , UK
11:10-11:20	No: <u>Rodrigo Abreu Gonzalez</u> , Spain	11:10-11:20	No: <u>Marta Pazos</u> , Spain
11:20-11:30	Discussion	11:20-11:30	Discussion
11:30-12:00	Debate 3: Sustained drug delivery of anti-VEGF has a potential to be a significant treatment option for neovascular AMD and other retinal diseases	11:30-12:00	Debate 3: Preventing Glaucoma is possible and feasible
11:30-11:40	Yes: <u>Dan Martin</u> , USA	11:30-11:40	Yes: <u>Francesca Cordeiro</u> , UK
11:40-11:50	No: <u>Lloyd Clark</u> , USA	11:40-11:50	No: TBC
11:50-12:00	Discussion	11:50-12:00	Discussion
12:15-13:15	Industry Sponsored Luncheon Symposium <i>(Lunch boxes served 12:00-12:15)</i>	HALL A	
13:30-14:30	Industry-Sponsored Dessert Symposium <i>(Dessert boxes served 13:15-13:30)</i>	HALL A	
14:30-15:00	Coffee Break, Visit Exhibition, View ePosters & join us in the Speakers’ Corner	EXHIBITION AREA	



FRIDAY, APRIL 4, 2025			
HALL A		HALL B	
15:00-16:30	SURGICAL RETINA 1 Controversial Approaches to Common Surgical Questions	15:00-16:30	GLAUCOMA 2
Chairs:	<u>William F. Mieler</u> , USA, <u>Jose Garcia-Arumi</u> , Spain; <u>Young Hee Yoon</u> , Korea	Chairs:	<u>Francesca Cordeiro</u> , UK
15:00-15:30	Debate 1: Inverted flap technique is the best surgical approach for large recurrent macular holes in high myopes	15:00-15:30	Debate 1: Should Glaucoma be managed by comprehensive ophthalmologists or Glaucoma specialists?
15:00-15:10	Yes: <u>Zofia Anna Nawrocka</u> , Poland	15:00-15:10	Yes: TBC
15:10-15:20	No: <u>Jose Garcia-Arumi</u> , Spain	15:10-15:20	No: <u>Joel Suarez</u> , Spain
15:20-15:30	Discussion	15:20-15:30	Discussion
15:30-16:00	Debate 2: In the setting of a phakic macula-on retinal detachment, with a superior retinal tear, comparable successful anatomic and visual outcomes can be achieved with either a vitrectomy, or with a scleral buckle	15:30-16:00	Debate 2: Glaucoma drops should be Preservative Free from first line
15:30-15:40	Yes: <u>Zofia Anna Nawrocka</u> , Poland	15:30-15:40	Yes: TBC
15:40-15:50	No: <u>Diego Ruiz Casas</u> , Spain	15:40-15:50	No: <u>Antonio Ferreras</u> , Spain
15:50-16:00	Discussion	15:50-16:00	Discussion
16:00-16:30	Debate 3: Pars plana vitrectomy is safe and effective in the management of symptomatic vitreous floaters	16:00-16:30	Debate 3: Tradition or Innovation? Trabeculectomy versus Minimally Invasive Bleb-based surgeries.
16:00-16:10	Yes: <u>Isabel Relimpio</u> , Spain	16:00-16:10	Tradition: TBC
16:10-16:20	No: <u>William F. Mieler</u> , USA	16:10-16:20	Innovation: <u>Sheng Lim</u> , UK
16:20-16:30	Discussion	16:20-16:30	Discussion



The 16th Annual Congress on Controversies in Ophthalmology: COPHy 2025
April 4-5, Seville, Spain

FRIDAY, APRIL 4, 2025		HALL A
16:30-17:30	VISION ACADEMY IN RETINA 2025 New challenges within retinal diseases: Navigating the evolving treatment landscape	
Chairs:		
16:30-16:35	Introduction to the Vision Academy	
16:35-16:50	Rapid-fire presentations: <ul style="list-style-type: none">• Impact of residual retinal fluid on treatment outcomes in nAM)• Diagnosis and assessment of simultaneous GA and CNV/MNV• Cataract surgery and anti-VEGF management	
16:50-17:00	Q&A <i>Moderators:</i>	
17:00-17:25	Panel discussion / Q&A: Expert opinion on the use of new treatment regimens with extended injection intervals <i>Moderators:</i> <i>Panelists:</i> Group discussion: All	
17:25-17:30	Session close	
17:30-18:30	Industry Sponsored Symposium	HALL A
18:30-19:30	Welcome Reception	
End of Day		



The 16th Annual Congress on Controversies in Ophthalmology: COPHY 2025
April 4-5, Seville, Spain

SATURDAY, APRIL 5, 2025			
07:30-08:30	Industry Sponsored Breakfast Symposium <i>(Light breakfast will be served from 07:00-07:30 at the entrance of the hall)</i>	HALL A	
	HALL A		HALL B
08:30-10:00	MEDICAL RETINA 2 Diabetic Macular Edema (DME) and Proliferative Diabetic Retinopathy	08:30-10:00	NEURO-OPHTHALMOLOGY 1 The Afferent Pathway
Chairs:	Francesco Bandello , Italy, Jose Maria Ruiz Moreno , Spain; Rufino Silva , Portugal	Chair:	Andrew G. Lee , USA
08:30-09:00	Debate 1: Steroid Therapy for DME is still relevant in the Era of New Generation Anti-VEGF agents	08:30-09:00	Debate 1: All acute ON patients require high dose corticosteroids
08:30-08:40	Yes: Francesco Bandello , Italy	08:30-08:40	Yes: Andrew G. Lee , USA
08:40-08:50	No: Juan Donate Lopez , Spain	08:40-08:50	No: Dan Milea , France
08:50-09:00	Discussion	08:50-09:00	Discussion
09:00-09:30	Debate 2: Oral Therapy for NPDR will be adopted as primary approach to management of NPDR	09:00-09:30	Debate 2: Temporal artery (TA) ultrasound should replace TA biopsy in GCA
09:00-09:10	Yes: Paolo Lanzetta , Italy	09:00-09:10	Yes: Susan Mollan , UK
09:10-09:20	No: Jorge Ruiz Medrano , Spain	09:10-09:20	No: Andrew G. Lee , USA
09:20-09:30	Discussion	09:20-09:30	Discussion
09:30-10:00	Debate 3: Novel topical steroids will become standard of care for initial therapy in mild DME	09:30-10:00	Case Presentations: Afferent
09:30-09:40	Yes: Baruch Kuppermann , USA		<i>Moderator: Andrew G. Lee, USA</i>
09:40-09:50	No: Francesco Boscia , Italy		<i>Panelists: All Speakers</i>
09:50-10:00	Discussion		
10:00-10:30	Coffee Break, Visit Exhibition, View ePosters & join us in the Speakers' Corner	EXHIBITION AREA	



SATURDAY, APRIL 5, 2025

HALL A		HALL B	
10:30-12:00	MEDICAL RETINA 3 Novel Technologies and Therapies in Retinal Diseases	10:30-12:00	UVEITIS 1
Chairs:	<u>Dinah Zur</u>, Israel; <u>Maribel Lopez Galvez</u>, Spain; <u>Enrique Rodriguez de la Rua</u>, Spain	Chairs:	<u>Bahram Bodaghi</u>, France; <u>Zohar Habot-Wilner</u>, Israel
10:30-11:00	Debate 1: Multi-pathway or high dose inhibitors improve DME biomarkers more than previous treatments	10:30-11:00	Debate 1: The use of biosimilars in uveitis
10:30-10:40	Yes: <u>Enrique Rodriguez de la Rua</u> , Spain	10:30-10:40	Yes: <u>Zohar Habot-Wilner</u> , Israel
10:40-10:50	No: <u>Dinah Zur</u> , Israel	10:40-10:50	No: <u>Sofia Androudi</u> , Greece
10:50-11:00	Discussion	10:50-11:00	Discussion
11:00-11:30	Debate 2: Existing outcome measures are sufficient to demonstrate the efficacy of new therapies for inherited retinal diseases	11:00-11:30	Debate 2: Prophylactic laser retinopexy and early pars plana vitrectomy (PPV) for preventing retinal detachment (RD) in acute retinal necrosis
11:00-11:10	Yes: <u>Enrique Rodriguez de la Rua</u> , Spain	11:00-11:10	Yes: <u>Alfredo Adán Civera</u> , Spain
11:10-11:20	No: <u>Dinah Zur</u> , Israel	11:10-11:20	No: <u>Sofia Androudi</u> , Greece
11:20-11:30	Discussion	11:20-11:30	Discussion
11:30-12:00	Debate 3: Blocking more than VEGFA can help in improving visual acuity in retinal disease	11:30-12:00	Debate 3: HLA - testing is mandatory in the investigation of posterior uveitis
11:30-11:40	Yes: <u>Young Hee Yoon</u> , Korea	11:30-11:40	Yes: <u>Bahram Bodaghi</u> , France
11:40-11:50	No: <u>Luis Arias</u> , Spain	11:40-11:50	No: <u>Ester Carreño</u> , Spain
11:50-12:00	Discussion	11:50-12:00	Discussion
12:15-13:15	Industry-Sponsored Luncheon Symposium <i>(Lunch boxes served 12:00-12:15)</i>		HALL A
13:30-14:30	Industry-Sponsored Dessert Symposium <i>(Dessert boxes served 13:15-13:30)</i>		HALL A
14:30-15:00	Coffee Break, Visit Exhibition, View ePosters & join us in the Speakers' Corner		EXHIBITION AREA



The 16th Annual Congress on Controversies in Ophthalmology: COPHY 2025
April 4-5, Seville, Spain

SATURDAY, APRIL 5, 2025

HALL A		HALL B	
15:00-16:30	SURGICAL RETINA 2 Controversies in the Utilization of Cutting Edge Vitreoretinal Surgical Technology	15:00-16:30	NEURO-OPHTHALMOLOGY 2 The Efferent Pathway
Chairs:	<u>William F. Mieler</u>, USA, <u>Jose Maria Ruiz-Moreno</u>, Spain; <u>Mark Humayun</u>, USA	Chair:	<u>Andrew G. Lee</u>, USA
15:00-15:30	Debate 1: Artificial Intelligence (AI) can predict the success of retinal detachment surgery	15:00-15:30	Debate 1: Functional visual loss is an organic disease
15:00-15:10	Yes: <u>Stanislao Rizzo</u> , Italy	15:00-15:10	Yes: <u>Susan Mollan</u> , UK
15:10-15:20	No: <u>Francesco Boscia</u> , Italy	15:10-15:20	No: <u>Dan Milea</u> , France
15:20-15:30	Discussion	15:20-15:30	Discussion
15:30-16:00	Debate 2: Heavy silicone is the most beneficial adjuvant in the successful management of a retinal detachment with proliferative vitreoretinopathy (PVR)	15:30-16:00	Debate 2: IIH is a medical not surgical disease now...
15:30-15:40	Yes: <u>Stanislao Rizzo</u> , Italy	15:30-15:40	Yes: <u>Susan Mollan</u> , UK
15:40-15:50	No: <u>Jose Garcia-Arumi</u> , Spain	15:40-15:50	No: <u>Andrew G. Lee</u> , USA
15:50-16:00	Discussion	15:50-16:00	Discussion
16:00-16:30	Debate 3: Multifocal or Extended Depth of Focus (EDOF) IOLs can be employed after successful repair of a macula-off retinal detachment	16:00-16:30	Case Presentations: Efferent
16:00-16:10	Yes: <u>William Mieler</u> , USA		<i>Moderator: <u>Susan Mollan</u>, UK</i>
16:10-16:20	No: <u>Mari Carmen Desco</u> , Spain		<i>Panelists: All Speakers</i>
16:20-16:30	Discussion		



The 16th Annual Congress on Controversies in Ophthalmology: COPHY 2025
April 4-5, Seville, Spain

SATURDAY, APRIL 5, 2025

HALL A		HALL B	
16:30-18:00	MEDICAL RETINA 4 New Treatment Strategies	16:30-18:00	UVEITIS 2
Chairs:	<u>Michaella Goldstein</u> , Israel; <u>Esther Ciancas</u> , Spain	Chairs:	<u>Bahram Bodaghi</u> , France; <u>Zohar Habot-Wilner</u> , Israel
16:30-17:00	Debate 1: Functional outcomes need to be used for assessment of treatment effects of drugs for non neovascular Age Related Macular Degeneration	16:30-17:00	Debate 1: Systemic therapy is the best option to control uveitic macular edema
16:30-16:40	Yes: <u>Michaella Goldstein</u> , Israel	16:30-16:40	Yes: <u>Alejandro Fonollosa Calduch</u> , Spain
16:40-16:50	No: <u>Jean-Francois Korobelnik</u> , France	16:40-16:50	No: <u>Zohar Habot-Wilner</u> , Israel
16:50-17:00	Discussion	16:50-17:00	Discussion
17:00-17:30	Debate 2: Photobiomodulation is a viable treatment in non neovascular AMD	17:00-17:30	Debate 2: Post-operative macular edema may be considered and managed as a uveitis
17:00-17:10	Yes: TBC	17:00-17:10	Yes: <u>Bahram Bodaghi</u> , France
17:10-17:20	No: <u>Jordi Monés</u> , Spain	17:10-17:20	No: <u>Alfredo Adán Civera</u> , Spain
17:20-17:30	Discussion	17:20-17:30	Discussion
17:30-18:00	Debate 3: Complement inhibition for geographic atrophy has more benefit than risk	17:30-18:00	Debate 3: Inflammatory choroidal neovascularization may be treated by anti-VEGFs alone
17:30-17:40	Yes: <u>Jordi Monés</u> , Spain	17:30-17:40	Yes: <u>Alejandro Fonollosa Calduch</u> , Spain
17:40-17:50	No: <u>Jean-Francois Korobelnik</u> , France	17:40-17:50	No: <u>Ester Carreño</u> , Spain
17:50-18:00	Discussion	17:50-18:00	Discussion
End of Congress			